Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.51 |
| ▸ | DPP4 | P27487 | 5/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707036 | 1.00 | DPP7 (0.51) | DPP7DPP4DPP8DPP9MMP1 | |
| SCHEMBL1707035 | 1.00 | DPP7 (0.51) | DPP7DPP4DPP8DPP9MMP1 | |
| SCHEMBL18774974 | 0.98 | MMP1 (0.51) | DPP7DPP4DPP8DPP9MMP1 | |
| Hydrochloric Acid SCHEMBL11172704 | 0.98 | DPP7 (0.50) | DPP7DPP4DPP8DPP9MMP1 | |
| Hydrochloric Acid SCHEMBL11181621 | 0.96 | DPP7 (0.50) | DPP7DPP4DPP8DPP9MMP1 | |
| SCHEMBL13995145 | 0.85 | DPP4 (0.45) | DPP7DPP4DPP8DPP9SLC7A5 | |
| SCHEMBL20413342 | 0.85 | DPP4 (0.45) | DPP7DPP4DPP8DPP9SLC7A5 | |
| SCHEMBL23996277 | 0.83 | DPP4 (0.44) | DPP7DPP4DPP8DPP9SLC7A5 | |
| SCHEMBL17152248 | 0.83 | DPP7 (0.50) | DPP7DPP4DPP8DPP9SLC7A5 | |
| SCHEMBL7355494 | 0.83 | CYP3A4 (0.50) | DPP7DPP4DPP8DPP9SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210047347-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10912750-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10752644-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| EP-2897939-B1 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES FOR TREATING METABOLIC OR CARDIOVASCULAR DISEASES | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| US-9156796-B2 | Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators | SANOFI (FR) | 2015-10-13 | — | — | US | disclosed |
| WO-2004103993-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| EP-1086083-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1086083-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064399-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | DPP7 3289/4885DPP4 2692/4885DPP8 3160/4885 |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | DPP7 3289/4885DPP4 2692/4885DPP8 3160/4885 |
| US-20210047347-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | DPP7 3289/4885DPP4 2692/4885DPP8 3160/4885 |
| US-10912750-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | DPP7 3289/4885DPP4 2692/4885DPP8 3160/4885 |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | DPP7 3289/4885DPP4 2692/4885DPP8 3160/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | DPP7 3289/4885DPP4 2692/4885DPP8 3160/4885 |
| US-10752644-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | DPP7 3289/4885DPP4 2692/4885DPP8 3160/4885 |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | DPP7 3289/4885DPP4 2692/4885DPP8 3160/4885 |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | DPP7 3289/4885DPP4 2692/4885DPP8 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.